XXXX Target of @entity3446 Inhibitor Monotherapy: Efficacy in Renal Transplantation.

@entity1 @entity644 @entity6 @entity9908 @entity1307 @entity2251 @entity3446 @entity551 @entity204 @entity4667
BACKGROUND: Calcineurin inhibitors (CNI) have failed to improve long-term outcomes in renal transplantation. Anti-proliferative and anti-angiogenic effects of @entity1 target of @entity3446 inhibitors (m- @entity9908 ) without nephrotoxicity could improve long-term survival in selected transplant recipients. METHODS: We examined the evolution of 98 low-immunological risk renal transplant recipients on m- @entity9908 monotherapy: 7 @entity1 had induction without CNI and 91 were switched to m- @entity9908 at 12 ( @entity4667 - @entity2251 : 4-36) months after transplant. RESULTS: Median follow-up time was 46 ( @entity4667 - @entity2251 : 28.5-72.0) months. Fifteen recipients dropped out of the study (15.3%): 8 @entity1 (8.2%) had to change their immunosuppressive treatment because of complications and 7 (7.1%) lost their grafts as a result of chronic rejection (4 cases) or @entity204 with a functioning graft (3 cases). At the end of follow-up, 83 of 98 (84.6%) recipients remained on monotherapy. The rates of recipient and graft survivals were 100% and 98.8% at 2 years and 96.9% and 93.5% at 4 years; the percentages of @entity1 on monotherapy after 2 and 4 years were 95.2% and 85.2%, respectively. Renal function improved significantly and @entity644 decreased but not significantly. Those @entity1 switched to m- @entity9908 significantly received more @entity1307 , angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and @entity551 agents than before starting m- @entity9908 , whereas there were no significant changes related to the use of statins, body weight, or percentage of @entity6 @entity1 . No case of non-compliance was reported. CONCLUSIONS: This study supports the safety and efficacy of monotherapy with m- @entity9908 in selected renal transplant recipients.
